NR4A1 and subependymal giant cell astrocytoma: Currently, everolimus is registered for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor-2 negative (HER2−) breast cancer in postmenopausal women in combination with exemestane, for metastatic renal cell carcinoma (mRCC), and for irresectable or metastatic pancreatic neuroendocrine tumors (pNET) and subependymal giant cell astrocytoma (SEGA) [2–4].